SFL-0821
Asset
Silences DUX4 expression using RNA interference in muscle cells.
- Stage
- Phase 1
- Modality
- Oligonucleotide
- Target
- DUX4
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Facioscapulohumeral muscular dystrophy
Phase 1, Recruiting, NCT07798609, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Competitors2
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.